Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupHistiocytic and Dendritic NeoplasmsDiseaseHemophagocytic LymphohistiocytosisSubgroupICD10D76.1MeSHLymphohistiocytosis, HemophagocyticMacrophage Activation SyndromeSequenceLDOX25/ETOP100/PRED20, HLH, A (PID947) -|- ETOP100/PRED0,4, HLH, B (PID1039)ChemotherapyChemo-substanceDexamethasoneDoxorubicin liposomalEmapalumabEtoposidePrednisoloneRuxolitinibChemo-substanceDexamethasoneDoxorubicin liposomalEmapalumabEtoposidePrednisoloneRuxolitinibChemo-substanceDexamethasoneDoxorubicin liposomalEmapalumabEtoposidePrednisoloneRuxolitinibChemo-substanceDexamethasoneDoxorubicin liposomalEmapalumabEtoposidePrednisoloneRuxolitinibNo. Substances123 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BAnakinraBalanced Crystalloid SolutionCotrimoxazoleFluconazoleGranisetronHuman immunoglobulin (IVIg)Supportive substanceAciclovirAmphotericin BAnakinraBalanced Crystalloid SolutionCotrimoxazoleFluconazoleGranisetronHuman immunoglobulin (IVIg)Supportive substanceAciclovirAmphotericin BAnakinraBalanced Crystalloid SolutionCotrimoxazoleFluconazoleGranisetronHuman immunoglobulin (IVIg)Supportive substanceAciclovirAmphotericin BAnakinraBalanced Crystalloid SolutionCotrimoxazoleFluconazoleGranisetronHuman immunoglobulin (IVIg)No. Substances146Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRefractory diseaseseveral possibleTherapy phaseInductionTherapy intentioncurativeRisksEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HepatotoxicityHypertensionHypokalemiaInfectionsInfusion ReactionPneumonitisRenal FailureShock only studiesPublicationAuthorAhmed AEhl SLocatelli FShakoory BWang YZhou DDiseaseHämophagozytische LymphohistiozytoseHämophagozytische Lymphohistiozytose des ErwachsenenMAS-like SepsisPrimäre hämophagozytische Lymphohistiozytose, neu diagnostiziert oder nach Versagen oder Unverträglichkeit der Primärtherapie, unter 18 JahrenTherapierefraktäre Hämophagozytische Lymphohistiozytose des ErwachsenenOriginCenter for Chronic Immunodeficiency, Faculty of Medicine, University of Freiburg, Freiburg, Germany, modifiziertes HLH-94 ProtokollDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Pediatrics, Sapienza, University of Rome, ItalyDivision of Rheumatology, Department of Medicine, George Washington University, Washington, USAThe First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR ChinaUniversity of Michigan Rogel Cancer Center, Ann Arbor, USAProtocols in Revision 7 protocols foundProtocols under revision.Anakinra 1, Macrophage activation syndrome in Hemophagocytic Lymphohistiocytosis (PID649 V1.0)Doxorubicin Liposomal 25 / Etoposide 100 / Prednisolone 20 - Etoposide 100 / Prednisolone 0.4, Hemophagocytic Lymphohistiocytosis, Part A (PID947 V1.1)Doxorubicin Liposomal 25 / Etoposide 100 / Prednisolone 20 - Etoposide 100 / Prednisolone 0.4, Hemophagocytic Lymphohistiocytosis, Part B (PID1039 V1.2)Emapalumab 1, Hemophagocytic Lymphohistiocytosis (PID848 V1.0)Etoposide 100 / Dexamethasone 10, Hemophagocytic Lymphohistiocytosis (PID1652 V1.0)Ruxolitinib 15 / Dexamethasone (10/5/2.5/1.25), Hemophagocytic Lymphohistiocytosis (PID2596 V1.0)Ruxolitinib 15, Hemophagocytic Lymphohistiocytosis (PID1041 V1.0)
